Prodrugs View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1985-05

AUTHORS

V. J. Stella, W. N. A. Charman, V. H. Naringrekar

ABSTRACT

Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules. More... »

PAGES

455-473

References to SciGraph publications

  • 1975. Drug Latentiation in CONCEPTS IN BIOCHEMICAL PHARMACOLOGY
  • 1972. Drug Action: Target Tissue, Dose-Response Relationships, and Receptors in PHARMACOLOGY AND PHARMACOKINETICS
  • 1977-02. Targeting of drugs in NATURE
  • 1979-10. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1958-08. Chemical Aspects of Selective Toxicity in NATURE
  • 1976-05. Ampicillin: Comparison of bioavailability and pharmacokinetics after oral and intravenous administration of three brands in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1976. Clinical Pharmacological Studies with Bacampicillin in PENICILLINS AND CEPHALOSPORINS
  • 1962. Drug Latentiation in FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG / PROGRESS IN DRUG RESEARCH / PROGRÈS DES RECHERCHES PHARMACEUTIQUES
  • 1981-09. Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Journal

    TITLE

    Drugs

    ISSUE

    5

    VOLUME

    29

    Related Patents

  • Methods And Compositions For Increasing Neurogenesis And Angiogenesis
  • Composition And Method For Muscle Repair And Regeneration
  • Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • Composition And Method For Muscle Repair And Regeneration
  • Targeted Drug Delivery Via Mixed Phosphate Derivatives
  • Calmodulin Inhibitors For The Treatment Of Ribosomal Disorders And Ribosomapathies
  • Calcium Channel Blockers For The Treatment Of Ribosomal Disorders And Ribosomapathies
  • Triptolide Lactone Ring Derivatives As Immunomodulators And Anticancer Agents
  • Phosphate Prodrugs; Treating Hiv Infection; 1-(Phosphomethyl)-3-(2-(4-Benzoylpiperazin-1-Yl)-1,2-Dioxoethyl)-4,7-Dimethoxy-1h-Pyrrolo(2,3-C)Pyridine For Example; Improved Water Solubility, Bioavailability For Oral Administration
  • Aminoquinoline Derivatives And Uses Thereof
  • Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity
  • Compositions And Methods For Treating Fibrosis
  • Random Amorphous Terpolymer Containing Lactide And Glycolide
  • Salts Of Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • Substituted Pyrazinone Derivatives For Use In Mch-1 Mediated Diseases
  • Shear Controlled Release For Stenotic Lesions And Thrombolytic Therapies
  • Delta-2 Opioid Receptor Agonists; Protecting Cardiac And Cerebral Organs
  • Use Of Anti-Histaminics For Acute Reduction Of Elevated Intracranial Pressure
  • Drug Combinations With Fluoro-Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
  • Treatment Of Sexual Dysfunction
  • Antibody-Enzyme Conjugates In Combination With Prodrugs For The Delivery Of Cytotoxic Agents To Tumor Cells
  • Improved Raf Inhibitors
  • Coating Comprising A Terpolymer Comprising Caprolactone And Glycolide
  • Polymers Comprising Amorphous Terpolymers And Semicrystalline Blocks
  • Inhibitors Of Phosphodiesterases 11 (Pde11) And Methods Of Use To Elevate Cortisol Production
  • Biodegradable Polymeric Materials Providing Controlled Release Of Hydrophobic Drugs From Implantable Devices
  • Coating Comprising A Terpolymer Comprising Caprolactone And Glycolide
  • Methods And Compositions For Increasing Neurogenesis And Angiogenesis
  • Directed Delivery Of Agents To Neural Anatomy
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • Bicyclo (3.1.0) Hexane-2, 6-Dicarboxylic Acid Derivatives As Mglu2 Receptor Agonist
  • Identification And Screening Of Triptolide Target Molecules
  • Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  • Triptolide Derivatives For Modulation Of Apoptosis And Immunosuppression
  • Aminoquinoline Derivatives And Uses Thereof
  • Inhibitors Of Late Sv40 Factor (Lsf) As Cancer Chemotherapeutics
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • 4-{4-[({3-Tert-Butyl-1-[3-(Hydroxymethyl) Phenyl]-1h-Pyrazol-5-Yl } Carbamoyl)-Amino] -3-Fluorophenoxy} -N-Methylpyridine-2-Carboxamide As Well As Prodrugs And Salts Thereof For The Treatment Of Cancer
  • Substituted Amino Isoxazoline Derivatives And Their Use As Anti-Depressants
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Useful As Immunosuppressive, Anti-Inflammatory And Anticancer Agents; Prepared By Reaction Of A Starting Triptolide Compound With Selenium Dioxide.
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Conjugate-Based Antifungal And Antibacterial Prodrugs
  • An Absorbable Coating For Implantable Device
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • New Drug For Inhibiting Aggregation Of Proteins Involved In Diseases Linked To Protein Aggregation And/Or Neurodegenerative Diseases
  • An Absorbable Coating For Implantable Device
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • Water Soluble Antibiotics
  • Synergistic Combination Or Single Ingredient Hiv And Aids Treatments
  • Methods For Treating Resistant Or Refractory Tumors
  • Methods And Compositions For Rejuvenating Skeletal Muscle Stem Cells
  • Terpolymers Containing Lactide And Glycolide
  • Salts Of Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • An Absorbable Coating For Implantable Device
  • Growth Differentiation Factor (Gdf) For Treatment Of Diastolic Heart Failure
  • Pro-Drugs For Cck Antagonists
  • Drug Combinations With Substituted Diaryl Ureas For The Treatment Of Cancer
  • Inhibitors Of Fructose 1,6-Bisphosphatase And Methods Of Use Thereof
  • Dihydropteridinones As Plk Inhibitors
  • Substituted Carbonate And Carbamate Derivatives Of Triptolide Compounds As Anticarcinogenic And Antiinflammatory Agents
  • 4-{4- [ ({3-Tert-Butyl-1- [3- (Hydroxymethyl) Phenyl] - 1h- Pyrazol- 5 -Yl } Carbamoyl) -Amin O] -3-Chlorophenoxy} -N-Methylpyridine-2-Carboxamide As An Inhibitor Of The Vegfr Kinase For The Treatment Of Cancer
  • Targeted Drug Delivery Via Mixed Phosphate Derivatives
  • Methods For Isolation Of Triptolide Compounds From Tripterygium Wilfordii
  • Tri-Block Copolymer Comprising Two Polyester Blocks And A Poly(Ethylene Glycol) Block
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002

    DOI

    http://dx.doi.org/10.2165/00003495-198529050-00002

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1022482439

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3891303


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Absorption", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenal Cortex Hormones", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood-Brain Barrier", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chloramphenicol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Stability", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug-Related Side Effects and Adverse Reactions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pain", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pharmaceutical Preparations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phenytoin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Solubility", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulindac", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Taste", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stella", 
            "givenName": "V. J.", 
            "id": "sg:person.010653152735.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010653152735.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Charman", 
            "givenName": "W. N. A.", 
            "id": "sg:person.01166642247.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166642247.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Naringrekar", 
            "givenName": "V. H.", 
            "id": "sg:person.016474031570.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016474031570.97"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/182421a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028596561", 
              "https://doi.org/10.1038/182421a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-46314-3_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051654474", 
              "https://doi.org/10.1007/978-3-642-46314-3_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4684-3126-1_19", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038094483", 
              "https://doi.org/10.1007/978-1-4684-3126-1_19"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00558335", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026583165", 
              "https://doi.org/10.1007/bf00558335"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/265407a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016845186", 
              "https://doi.org/10.1038/265407a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1981.174", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028323260", 
              "https://doi.org/10.1038/clpt.1981.174"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4684-2055-5_9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027313220", 
              "https://doi.org/10.1007/978-1-4684-2055-5_9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-0348-7044-3_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039902569", 
              "https://doi.org/10.1007/978-3-0348-7044-3_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01062386", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028952932", 
              "https://doi.org/10.1007/bf01062386"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1985-05", 
        "datePublishedReg": "1985-05-01", 
        "description": "Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003495-198529050-00002", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1084788", 
            "issn": [
              "0012-6667", 
              "1179-1950"
            ], 
            "name": "Drugs", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "29"
          }
        ], 
        "keywords": [
          "drug molecules", 
          "parent drug molecule", 
          "chemical experience", 
          "chemical derivatives", 
          "prodrug approach", 
          "molecules", 
          "prodrug", 
          "clinical efficacy", 
          "clinical usefulness", 
          "active drug", 
          "scientific rationale", 
          "derivatives", 
          "drugs", 
          "efficacy", 
          "review", 
          "transformation", 
          "rationale", 
          "usefulness", 
          "experience", 
          "body", 
          "means", 
          "order", 
          "example", 
          "different ways", 
          "design", 
          "approach", 
          "way", 
          "problem"
        ], 
        "name": "Prodrugs", 
        "pagination": "455-473", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1022482439"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003495-198529050-00002"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3891303"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003495-198529050-00002", 
          "https://app.dimensions.ai/details/publication/pub.1022482439"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:46", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_203.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003495-198529050-00002"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'


     

    This table displays all metadata directly associated to this object as RDF triples.

    195 TRIPLES      21 PREDICATES      77 URIs      60 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003495-198529050-00002 schema:about N1e539b418aa64a0993718255b3550910
    2 N20e72a740f874d69a4a7478b8f0ac1b5
    3 N23ec49a166a640f5ae775865763f848e
    4 N34e1b9e3d24442c2956fb8c4e7864eef
    5 N4957fba8e3c44a748ba668bd5556fce9
    6 N497568607aea44a3b24b8d5aada505b4
    7 N8553746bd7c9448a859f1c6373c82af6
    8 N98ccefdc41c24686b05f57478324a4d7
    9 N9b8386141a844c6c9a4275b2f97ed376
    10 Nacbb8736caee43bda3cf522fdfd39c62
    11 Nb2b6214f814e46cca78a1c713ce34aa0
    12 Nb3c699197bba47a4b05e69ff04e96068
    13 Nc2135b88db434e7b84566058695f0c72
    14 Ne67e8c3bdeb84c7dbcbc85c3f6c8bb5a
    15 anzsrc-for:11
    16 anzsrc-for:1115
    17 schema:author N2f6fa7d63899436b8170febc0dc884cd
    18 schema:citation sg:pub.10.1007/978-1-4684-2055-5_9
    19 sg:pub.10.1007/978-1-4684-3126-1_19
    20 sg:pub.10.1007/978-3-0348-7044-3_2
    21 sg:pub.10.1007/978-3-642-46314-3_3
    22 sg:pub.10.1007/bf00558335
    23 sg:pub.10.1007/bf01062386
    24 sg:pub.10.1038/182421a0
    25 sg:pub.10.1038/265407a0
    26 sg:pub.10.1038/clpt.1981.174
    27 schema:datePublished 1985-05
    28 schema:datePublishedReg 1985-05-01
    29 schema:description Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.
    30 schema:genre article
    31 schema:isAccessibleForFree false
    32 schema:isPartOf N086c7c3a3286427d91d79c819703dcc0
    33 N098d655e253f4f739dd567803bcf0817
    34 sg:journal.1084788
    35 schema:keywords active drug
    36 approach
    37 body
    38 chemical derivatives
    39 chemical experience
    40 clinical efficacy
    41 clinical usefulness
    42 derivatives
    43 design
    44 different ways
    45 drug molecules
    46 drugs
    47 efficacy
    48 example
    49 experience
    50 means
    51 molecules
    52 order
    53 parent drug molecule
    54 problem
    55 prodrug
    56 prodrug approach
    57 rationale
    58 review
    59 scientific rationale
    60 transformation
    61 usefulness
    62 way
    63 schema:name Prodrugs
    64 schema:pagination 455-473
    65 schema:productId N36511da590cb484d986630e76cb1b92d
    66 N56971300ca6e48e1846d878387303659
    67 N97e4cb79159d404a9ca918f4689e8e8d
    68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022482439
    69 https://doi.org/10.2165/00003495-198529050-00002
    70 schema:sdDatePublished 2022-09-02T15:46
    71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    72 schema:sdPublisher N27aeb4294e04487cbe30a9f983942c9e
    73 schema:url https://doi.org/10.2165/00003495-198529050-00002
    74 sgo:license sg:explorer/license/
    75 sgo:sdDataset articles
    76 rdf:type schema:ScholarlyArticle
    77 N086c7c3a3286427d91d79c819703dcc0 schema:issueNumber 5
    78 rdf:type schema:PublicationIssue
    79 N098d655e253f4f739dd567803bcf0817 schema:volumeNumber 29
    80 rdf:type schema:PublicationVolume
    81 N1e539b418aa64a0993718255b3550910 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    82 schema:name Humans
    83 rdf:type schema:DefinedTerm
    84 N20e72a740f874d69a4a7478b8f0ac1b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Pharmaceutical Preparations
    86 rdf:type schema:DefinedTerm
    87 N23ec49a166a640f5ae775865763f848e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Phenytoin
    89 rdf:type schema:DefinedTerm
    90 N27aeb4294e04487cbe30a9f983942c9e schema:name Springer Nature - SN SciGraph project
    91 rdf:type schema:Organization
    92 N2f6fa7d63899436b8170febc0dc884cd rdf:first sg:person.010653152735.32
    93 rdf:rest N47e6724088ac493fa85f226b9053435b
    94 N34e1b9e3d24442c2956fb8c4e7864eef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Solubility
    96 rdf:type schema:DefinedTerm
    97 N36511da590cb484d986630e76cb1b92d schema:name dimensions_id
    98 schema:value pub.1022482439
    99 rdf:type schema:PropertyValue
    100 N47e6724088ac493fa85f226b9053435b rdf:first sg:person.01166642247.11
    101 rdf:rest Na5b657e930104bedbddec393d42d87b8
    102 N4957fba8e3c44a748ba668bd5556fce9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Pain
    104 rdf:type schema:DefinedTerm
    105 N497568607aea44a3b24b8d5aada505b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Blood-Brain Barrier
    107 rdf:type schema:DefinedTerm
    108 N56971300ca6e48e1846d878387303659 schema:name pubmed_id
    109 schema:value 3891303
    110 rdf:type schema:PropertyValue
    111 N8553746bd7c9448a859f1c6373c82af6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Absorption
    113 rdf:type schema:DefinedTerm
    114 N97e4cb79159d404a9ca918f4689e8e8d schema:name doi
    115 schema:value 10.2165/00003495-198529050-00002
    116 rdf:type schema:PropertyValue
    117 N98ccefdc41c24686b05f57478324a4d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Drug-Related Side Effects and Adverse Reactions
    119 rdf:type schema:DefinedTerm
    120 N9b8386141a844c6c9a4275b2f97ed376 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Taste
    122 rdf:type schema:DefinedTerm
    123 Na5b657e930104bedbddec393d42d87b8 rdf:first sg:person.016474031570.97
    124 rdf:rest rdf:nil
    125 Nacbb8736caee43bda3cf522fdfd39c62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Sulindac
    127 rdf:type schema:DefinedTerm
    128 Nb2b6214f814e46cca78a1c713ce34aa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Drug Stability
    130 rdf:type schema:DefinedTerm
    131 Nb3c699197bba47a4b05e69ff04e96068 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Drug Therapy
    133 rdf:type schema:DefinedTerm
    134 Nc2135b88db434e7b84566058695f0c72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Chloramphenicol
    136 rdf:type schema:DefinedTerm
    137 Ne67e8c3bdeb84c7dbcbc85c3f6c8bb5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Adrenal Cortex Hormones
    139 rdf:type schema:DefinedTerm
    140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    141 schema:name Medical and Health Sciences
    142 rdf:type schema:DefinedTerm
    143 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    144 schema:name Pharmacology and Pharmaceutical Sciences
    145 rdf:type schema:DefinedTerm
    146 sg:journal.1084788 schema:issn 0012-6667
    147 1179-1950
    148 schema:name Drugs
    149 schema:publisher Springer Nature
    150 rdf:type schema:Periodical
    151 sg:person.010653152735.32 schema:affiliation grid-institutes:grid.266515.3
    152 schema:familyName Stella
    153 schema:givenName V. J.
    154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010653152735.32
    155 rdf:type schema:Person
    156 sg:person.01166642247.11 schema:affiliation grid-institutes:grid.266515.3
    157 schema:familyName Charman
    158 schema:givenName W. N. A.
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166642247.11
    160 rdf:type schema:Person
    161 sg:person.016474031570.97 schema:affiliation grid-institutes:grid.266515.3
    162 schema:familyName Naringrekar
    163 schema:givenName V. H.
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016474031570.97
    165 rdf:type schema:Person
    166 sg:pub.10.1007/978-1-4684-2055-5_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027313220
    167 https://doi.org/10.1007/978-1-4684-2055-5_9
    168 rdf:type schema:CreativeWork
    169 sg:pub.10.1007/978-1-4684-3126-1_19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038094483
    170 https://doi.org/10.1007/978-1-4684-3126-1_19
    171 rdf:type schema:CreativeWork
    172 sg:pub.10.1007/978-3-0348-7044-3_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039902569
    173 https://doi.org/10.1007/978-3-0348-7044-3_2
    174 rdf:type schema:CreativeWork
    175 sg:pub.10.1007/978-3-642-46314-3_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051654474
    176 https://doi.org/10.1007/978-3-642-46314-3_3
    177 rdf:type schema:CreativeWork
    178 sg:pub.10.1007/bf00558335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026583165
    179 https://doi.org/10.1007/bf00558335
    180 rdf:type schema:CreativeWork
    181 sg:pub.10.1007/bf01062386 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028952932
    182 https://doi.org/10.1007/bf01062386
    183 rdf:type schema:CreativeWork
    184 sg:pub.10.1038/182421a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028596561
    185 https://doi.org/10.1038/182421a0
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1038/265407a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016845186
    188 https://doi.org/10.1038/265407a0
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1038/clpt.1981.174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028323260
    191 https://doi.org/10.1038/clpt.1981.174
    192 rdf:type schema:CreativeWork
    193 grid-institutes:grid.266515.3 schema:alternateName Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA
    194 schema:name Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA
    195 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...